fexofenadine
fexofenadine: sourced relationships with 2 companies · 5 clinical trials tracked · 7 FDA decisions.
fexofenadine evidence translation
What we can confirm
7 FDA records · 5 tracked trials
What it means
What to watch
Prepared research question
What is verified about fexofenadine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) Reported 2013-01-18 · Current development: unknownSource | Approved |
| Sanofi (SNY) Reported 2007-07-26 · Current development: unknownSource Uses temporarily relieves these symptoms due to hay fever or… | Approved |
Clinical Trial Registry Records (5)
A Phase 1, 3-part, Open-label Study to Evaluate the Effects of KarXT Administration on the Pharmacokinetics of Midazolam, Fexofenadine, and Digoxin in Healthy Adult Participants
Primary endpoint: Part 1/1a: Geometric mean ratio (GMR) of Maximum observed plasma concentration (Cmax) of midazolam with and without KarXT
A Phase IV, Open Label, Clinical Trial to Assess Safety and Efficacy of Fexofenadine HCL + Pseudoephedrine HCL Fixed Dose Combination in Indian Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST Trial)
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs)
A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion
Primary endpoint: Percent Reduction in Shortest Tolerated Infusion Duration From Pre-study Average of Recent 3 Infusions
A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis
Primary endpoint: Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
Primary endpoint: Study A: Proportion of participants with improvement (reduction) in weekly average of daily worst-itch numerical rating scale (WI-NRS) by ≥4 from baseline to Week 24
FDA Decisions7 records
Frequently asked questions
Which companies have sourced relationships with fexofenadine?
fexofenadine has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD, Sanofi.
How many clinical trials involve fexofenadine?
BioSniper tracks 5 clinical trials involving fexofenadine.
What is fexofenadine's latest FDA decision?
The most recent tracked FDA decision for fexofenadine is Approval, dated July 30, 2026.